ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC) from September 7 – 10, 2024 in San Diego, California. Novocure will take part in presentations and symposia throughout the event and will exhibit several posters exploring the use of Tumor Treating Fields (TTFields) therapy in the treatment of lung cancer, including a new post-hoc analysis of data from the LUNAR trial in metastatic non-small cell lung cancer (NSCLC)..

瑞士ROOT——（商业新闻短讯）——Novocure（纳斯达克：NVCR）今天宣布参加即将于2024年9月7日至10日在加利福尼亚州圣地亚哥举行的国际肺癌研究协会（IASLC）2024年世界肺癌会议（WCLC）。Novocure将在整个活动期间参加演讲和专题讨论会，并将展示几张海报，探索肿瘤治疗领域（TTFields）治疗在肺癌治疗中的应用，包括对转移性非小细胞肺癌（NSCLC）LUNAR试验数据的新事后分析。。

“We are eager to share these exciting new analyses with the lung cancer community,” said Nicolas Leupin, MD, Novocure’s Chief Medical Officer. “TTFields therapy offers significant potential for the treatment of this prevalent disease. With multiple regulatory reviews underway, there is no better time to examine the promise of TTFields use in the treatment of NSCLC.”.

“我们渴望与肺癌界分享这些令人兴奋的新分析，”Novocure首席医疗官尼古拉斯·鲁平医学博士说。“TTFields疗法为治疗这种流行疾病提供了巨大的潜力。随着多项监管审查的进行，没有更好的时间来检查TTFields用于治疗NSCLC的前景。”。

The new post-hoc analysis evaluated survival data from the phase 3 LUNAR clinical trial, as well as a data from a simulation study, to assess the effect of body mass index (BMI) on overall survival (OS) and the feasibility of delivering TTFields at a therapeutic intensity to patients of varying BMIs.

新的事后分析评估了3期LUNAR临床试验的生存数据以及模拟研究的数据，以评估体重指数（BMI）对总生存期（OS）的影响以及向不同BMI患者提供TTFields治疗强度的可行性。

Investigators did not identify a difference in OS benefit between patients with a BMI <25 kg/m2 compared a BMI >25 kg/m2. Additionally, data from the simulation-based study suggests TTFields can be delivered to the lungs in therapeutic dose and a corresponding clinical benefit observed in patients across a range of BMIs..

研究人员没有发现BMI<25 kg/m2的患者与BMI>25 kg/m2的患者在OS获益方面存在差异。此外，基于模拟的研究数据表明，TTFields可以以治疗剂量传递到肺部，并且在一系列BMI的患者中观察到相应的临床益处。。

The LUNAR trial was designed to evaluate the use of TTFields therapy together with standard systemic therapies for the treatment of metastatic non-small cell lung cancer, following progression on or after platinum-based therapy. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful extension in OS for patients treated with TTFields and standard systemic therapies, as well as a pronounced extension in OS for patients randomized to receive physician’s choice immune checkpoint inhibitor together with TTFields.

LUNAR试验旨在评估在铂类治疗或铂类治疗后进展后，TTFields治疗与标准全身治疗一起用于治疗转移性非小细胞肺癌。该试验达到了其主要终点，证明了接受TTFields和标准全身治疗的患者的OS具有统计学意义和临床意义的延长，以及随机接受医生选择的免疫检查点抑制剂和TTFields治疗的患者的OS显着延长。

Novocure has submitted these data to regulatory agencies for approval and anticipates treating patients in late 2024..

Novocure已将这些数据提交给监管机构批准，并预计在2024年底治疗患者。。

Novocure’s presence at the 2024 WCLC will include:

Novocure在2024年WCLC的参展将包括：

Sunset Seminar: Women in Thoracic Oncology, hosted by Women Leaders in Oncology (WLO), sponsored by Novocure, on September 8, 2024, at 6:00 p.m. UTC-7

日落研讨会：女性在胸部肿瘤学，由女性肿瘤学领袖（WLO）主办，由Novocure赞助，于2024年9月8日下午6:00 UTC-7

Impact of BMI on TTFields in Patients with mNSCLC: Post-hoc Analysis from the Phase 3 LUNAR Study and Simulation Model Data. Poster P1.098B.04 displayed in the Exhibit Hall on September 8, 2024, at 12:00 p.m. UTC-7

BMI对mNSCLC患者TTFields的影响：来自3期LUNAR研究和模拟模型数据的事后分析。海报P1.098B.04于2024年9月8日下午12:00 UTC-7在展厅展出

Treatment of Non-Small Cell Lung Carcinoma (NSCLC) Cells With Tumor Treating Fields (TTFields) and DNA-Dependent Protein Kinase (PK) Inhibitors. E-Poster EP.03F.04

用肿瘤治疗场（TTFields）和DNA依赖性蛋白激酶（PK）抑制剂治疗非小细胞肺癌（NSCLC）细胞。电子海报EP.03F.04

Tumor Treating Fields (TTFields) Induce Pro-Inflammatory Phenotype Skewing of Macrophages. E-Poster EP.03G.03

肿瘤治疗场（TTFields）诱导巨噬细胞的促炎表型倾斜。电子海报EP.03G.03

ABOUT TUMOR TREATING FIELDS THERAPY

关于肿瘤治疗领域的治疗

Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells.

肿瘤治疗场（TTFields）是通过多种机制施加物理力杀死癌细胞的电场。TTFields不会显着影响健康细胞，因为它们具有与癌细胞不同的特性（包括分裂速率，形态和电特性）。

These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models.

这些多种不同的机制共同作用以靶向和杀死癌细胞。由于这些多机制作用，TTFields治疗可以在批准的适应症中添加到癌症治疗模式中，并且在临床前模型中与化疗，放疗，免疫检查点抑制或靶向治疗一起使用时，可以在实体瘤类型中显示出增强的效果。

TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfields.com..

TTFields疗法提供了临床多功能性，有可能帮助解决一系列实体瘤的治疗挑战。要了解更多有关肿瘤治疗场疗法及其对癌细胞的多方面影响的信息，请访问tumortreatingfields.com。。

ABOUT LUNAR

关于LUNAR

LUNAR tested the safety and effectiveness of TTFields therapy when used together with either an immune checkpoint inhibitor (ICI) or docetaxel for the treatment of patients diagnosed with metastatic NSCLC following progression on or after the use of platinum-based therapy. Patients randomized to receive TTFields therapy together with standard therapies (n=137) demonstrated median overall survival (OS) of 13.2 months compared to 9.9 months in patients treated with standard therapies alone (n=139).

LUNAR测试了TTFields治疗的安全性和有效性，当与免疫检查点抑制剂（ICI）或多西紫杉醇一起用于治疗使用铂类治疗后或使用铂类治疗后诊断为转移性NSCLC的患者时。随机接受TTFields治疗和标准治疗的患者（n=137）显示中位总生存期（OS）为13.2个月，而仅接受标准治疗的患者（n=139）为9.9个月。

Patients randomized to receive TTFields therapy and physician’s choice ICI (n=66) demonstrated a median OS of 18.5 months versus a median OS of 10.8 months in patients treated with an ICI alone (n=68; HR=0.63; P=0.03). Patients randomized to receive TTFields therapy and docetaxel (n=71) had a positive survival trend with a median OS of 11.1 months vs 8.7 months in patients treated with docetaxel alone (n=71).

随机接受TTFields治疗和医师选择ICI（n=66）的患者的中位OS为18.5个月，而单独使用ICI治疗的患者的中位OS为10.8个月（n=68；HR=0.63；P=0.03）。随机接受TTFields治疗和多西紫杉醇治疗的患者（n=71）的生存率呈阳性趋势，中位OS为11.1个月，而单用多西紫杉醇治疗的患者（n=71）的中位OS为8.7个月。

TTFields therapy was well-tolerated with no added systemic toxicities and few grade 3 (no grade 4 or 5) device-related adverse events..

TTFields治疗耐受性良好，无额外的全身毒性，3级（无4级或5级）器械相关不良事件很少。。

ABOUT NOVOCURE

关于新焦点

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma.

Novocure是一家全球性肿瘤公司，致力于通过其创新疗法，肿瘤治疗领域的开发和商业化，延长一些最具侵袭性的癌症的生存期。Novocure的商业化产品在某些国家被批准用于治疗成人胶质母细胞瘤和恶性胸膜间皮瘤患者。

Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer..

。。

Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter..

Novocure总部位于瑞士Root，全球足迹不断扩大，在朴茨茅斯、新罕布什尔州和东京设有区域运营中心，在以色列海法设有研究中心。有关该公司的更多信息，请访问Novocure.com，并在LinkedIn和Twitter上关注@Novocure。。

FORWARD-LOOKING STATEMENTS

前瞻性声明

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts.

除了历史事实或现状声明外，本新闻稿可能还包含前瞻性声明。前瞻性声明提供了Novocure目前对未来事件的预期或预测。。

You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2024, and subsequent filings with the U.S.

您可以通过在声明中使用诸如“预期”、“估计”、“预期”、“项目”、“打算”、“计划”、“相信”或其他类似含义的词语和术语来识别其中一些前瞻性声明。由于一般的财务、经济、环境、监管和政治条件以及Novocure面临的其他更具体的风险和不确定性，Novocure的业绩和财务结果可能与这些前瞻性报表中反映的业绩和财务结果存在重大差异，如2024年2月22日提交的10-K表年度报告以及随后提交给美国。

Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law.

证券交易委员会。鉴于这些风险和不确定性，任何或所有这些前瞻性陈述可能被证明是不正确的。因此，您不应依赖任何此类因素或前瞻性陈述。此外，Novocure不打算公开更新任何前瞻性声明，除非法律要求。

Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion..

本文件中的任何前瞻性声明仅在本文件日期起生效。1995年的《私人证券诉讼改革法案》允许进行这种讨论。。